LSD Educational Resources

Lysergic acid diethylamide (LSD) was first synthesised in 1938 by Albert Hoffman at the Sandoz AG Pharmaceutical Company in Basel, Switzerland LSD was the 25th lysergic acid derivative developed by Hoffman during a discovery project for pharmacologically active derivatives of lysergic acid which would act as a circulatory and respiratory stimulant LSD became widely used  …


Medical MDMA Educational Resources

MDMA (3,4-Methyl​enedioxy​methamphetamine) was first synthesised in 1912 by chemists at the pharmaceutical company, Merck in Germany. In 1985, MDMA was placed in schedule 1, resulting in no research being conducted into the potential therapeutic applications of MDMA between 1985 – 2000. However, since then, MDMA has been included in over 5000 academic articles and administered to  …


Medical Psilocybin Educational Resources

The psychotropic effects of Psilocybe mushrooms were largely unknown in the West until the 1950s, despite evidence that they had a long history of indigenous use in Central and South America, and possibly other parts of the world. Western civilisations had very little knowledge of this relatively ‘new‘ psychotropic and subsequently banned research into its  …


Response to the Nature article: Moving from prison to PhD

There are fewer than ten empirical studies on the transition from prison to university so the article “Moving from Prison to PhD” is a step in the right direction to highlight this neglected and important topic. Globally, millions of individuals are arrested and charged with drug offences every year. Most of them will be scarred  …


Response to the NICE recommendations

The National Institute for Health and Care Excellence (NICE) published their guidance to clinicians on the 11th of November 2019 regarding the prescribing of Cannabis-Based Medicinal Products (CBMPs). Drug Science welcomes this news from NICE as it shows the start of a more rational approach to medical cannabis. However, it must be emphasised that this  …


Project Twenty21 – Scientific Oversight Board

Project Twenty21 is committed to scientific excellence and the development of independent scientific evidence. It is supported by a scientific oversight board, consisting of the following expertise: Professor David Nutt DM, FRCP, FRCPSYCH, FSB, FMEDSCI. Professor of Neuropsychopharmacology at Imperial College London.   Professor Eileen Joyce MA, PhD, MB BChir, MRCP, FRCPsych Professor of Neuropsychiatry  …


Statement on the dangers posed by e-cigarettes

Drug Science stands by its e-cigarette analysis from 2014, any way of radically reducing the death toll from tobacco would be a worldwide public health triumph. e-cigarettes are not the solution to end the ever-increasing death toll caused by tobacco. However, they have proven to be an incredibly effective tool for tens of thousands of  …


New Zealand revises sentencing framework for methamphetamine offences

Dr James Foulds, Consultant forensic psychiatrist, Christchurch New Zealand Methamphetamine smoking is the commonest form of stimulant use in New Zealand. Asian importation has increased recently, and the drug has got much cheaper. However, despite harsh sanctions, dealing remains attractive for many people- including those who sell the drug to fund their own use. Until  …


Looking back on the establishment of Drug Science

I first came across David Nutt in July 2007, when he spoke at a conference called ‘Criminal Justice and Social Justice’, which the Centre for Crime and Justice Studies held at King’s College London. David spoke on the subject of ‘Why adopt a harm approach in relation to drugs?’. Here was someone, I thought at  …


Medical Cannabis Education

Drug Science is asked frequently about medical cannabis – what it is, what it can be used for, who can prescribe it and how to regulate it.  We’ve developed different ways to help doctors, patients and professionals understand this complex, emerging field, and our education programmes are central to this MEDIC (Medical Education in Cannabinoids)  …


NICE on cannabidiol for childhood epilepsy

At the end of last week, NICE released their initial appraisal on cannabidiol in the form of Epidiolex for childhood epilepsy.  As predicted by Drug Science experts they found against it on the grounds of cost-benefit. We don’t have the company submission regarding cost/benefit analysis, and consequently cannot comment on those, but we can reflect  …


Introducing The Drug Science Podcast

It is a great pleasure to announce the launch of The Drug Science Podcast.     As you well know, Drug Science exists to campaign for a more rational, evidence-based approach to drug policy and drug use. It is frustrating to say the least that still, in the 21st century, the debate on drugs, both  …


First safety study of MDMA-assisted psychotherapy in patients with alcohol use disorder

Authors: Ben Sessa, Chloe Sakal, Steve O’Brien and David Nutt Published: July 15, 2019 Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol  …

The Cannabis Society: London Medical Cannabis Conference

Drug Science is delighted to support The Cannabis Society Medical Conference, being held on 24th June in Central London. The Cannabis Society is dedicated to fostering the cannabis community through events, conferences, dinners and much more. The conference is an opportunity to join with doctors from both Europe and North America, industry experts, investors and  …


Drug Science's 10th birthday at the House of Lords: past achievements and a bright future

Drug Science Patron Lord Nic Rea, hosted Drug Science committee members, trustees, and community supporters at House of Lords on Wednesday, celebrating ten years of achievements, and new initiatives in medical cannabis and psychedelic research. In the beautiful Cholmondeley Room of Westminster Palace, 150 of Drug Science’s supporters heard CEO David Badcock welcome guests and  …


Cannabis health information labels: why it’s time to have mandatory warnings as part of any legal cannabis market

Prof. Adam Winstock – Global Drug Survey 2019 As the tide of cannabis regulatory reform wafts through North America and beyond, it strikes me that the cannabis legalisation lobby started from a strong position. The weight of evidence and cogent arguments at their disposal to counter the totally unhelpful criminalisation of cannabis users was enormous.  …


Drug Science gives evidence to the Health and Social Care Committee on Medicinal Cannabis

On 1 November 2018, following considerable popular pressure surrounding a select number of young children with treatment-resistant epilepsy who responded well to medicinal cannabis (and medicinal cannabis alone), regulations in the UK came into force to reschedule cannabis‑derived medicinal products to schedule 2 of the Misuse of Drugs Regulations 2001 and to allow prescribing of  …

The Global Commission on Drug Policy misses the mark

Author: Willem Scholten Published: November 22, 2018 The Global Commission on Drug Policy launched a report on the world drug (perception) problem, countering prejudices about people who use drugs, which includes remarks on the avoidance of stigmatizing terminology. Although many aspects of the report are helpful in moving the field forward, the report itself is  …

Controversies in substance misuse in the older person

There are a range of issues facing us in relation to substance misuse in the older person: some are ongoing controversies and uncertainties; some are myths; and others certainties. Much of these issues are covered in depth in a new report published by the Royal College of Psychiatrists this year – Our Invisible Addicts. There  …

The case of the Norwegian teen who died from synthetic cannabinoids

Author: Jon F Olsen Published: September 21, 2018 During the Easter holiday in 2015, 22-year-old Egil André Kvelstad Myhre was found dead in his apartment, after a cardiac arrest . Myhre was not a common drug user, as his family stated he had never done drugs before. Hours before his death, Myhre had attended a  …

ACMD advice on cannabis-derived medicinal products

On 11 September 2018, the ACMD published its Advice to the Home Secretary and to the Secretary of State for Health and Social Care. It is a constructive document that highlights a number of issues and problems that this commentator has raised for some time. In some respects the document is nuanced. Doubtless in the  …